Curat Global LLC Makes New $569,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Curat Global LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 5,080 shares of the biopharmaceutical company's stock, valued at approximately $569,000.

Several other institutional investors have also recently made changes to their positions in the stock. Norges Bank acquired a new position in Gilead Sciences in the 4th quarter valued at $1,789,254,000. FMR LLC grew its holdings in Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after buying an additional 7,157,113 shares in the last quarter. GAMMA Investing LLC grew its holdings in Gilead Sciences by 13,891.1% in the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock valued at $285,761,000 after buying an additional 2,532,070 shares in the last quarter. Northern Trust Corp grew its holdings in Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after buying an additional 2,458,954 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Gilead Sciences in the 4th quarter valued at $207,340,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on GILD shares. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Wells Fargo & Company upped their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Piper Sandler raised their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. BMO Capital Markets raised their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Trading Up 1.8%

Shares of GILD stock traded up $2.00 on Friday, hitting $112.46. The company had a trading volume of 5,263,529 shares, compared to its average volume of 7,750,058. The firm has a market cap of $139.89 billion, a P/E ratio of 303.95, a P/E/G ratio of 0.71 and a beta of 0.29. The stock's 50-day moving average is $105.39 and its two-hundred day moving average is $101.47. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a twelve month low of $62.69 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business's quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.32) earnings per share. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.81%. Gilead Sciences's payout ratio is 66.53%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the sale, the chief financial officer now owns 165,674 shares of the company's stock, valued at $16,537,578.68. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the sale, the chief executive officer now directly owns 620,268 shares of the company's stock, valued at $68,489,992.56. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold 60,929 shares of company stock valued at $6,748,980 over the last 90 days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.